SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors aggressively rotate into semiconductor stocks following strong sector-wide sentiment, with the community actively debating whether the current momentum is a sustainable long-term re-rating or an overextended bubble primed for a pullback ahead of earnings. While many investors are expressing high conviction in the CPU-to-GPU shift and the company's long-term growth narrative, bears are citing extreme technical indicators and elevated valuations as catalysts for potential near-term volatility.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining traction as a high-volatility meme coin, with the community actively rallying around the developer's commitment to avoiding rug pulls through transparent token burns and manual airdrops. Investors are currently hyper-focused on the project's growth potential and upcoming charting developments, urging others to buy and hold as they aim to hit key market cap milestones.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is currently a focus for investors as they navigate complex community debates regarding potential strategic partnerships, the impact of federal steel tariffs, and persistent concerns over debt levels. Community discussions are heavily centered on whether the company's vertically integrated domestic infrastructure will drive a long-term turnaround or if ongoing market manipulation and management decisions will continue to weigh on performance.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is experiencing a significant surge driven by the FDA’s decision to lift clinical holds on key gene-editing programs, which has triggered heavy buying pressure against a massive short interest. Investors are currently focused on the upcoming Phase 3 readout for HAE, viewing the company’s in vivo CRISPR technology as a potential game-changer that could redefine the biotech sector.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera Inc. is trending as investors aggressively speculate on a potential major commercial licensing deal following an expanded collaboration with Synopsys and ongoing work with key equipment partners in the semiconductor space. The community is sharply divided between retail bulls anticipating a breakout on high volume and skeptics who highlight the company's long history of pre-revenue status and capital-raising activities.

Magnachip Semiconductor Corp. engages in the design and manufacture of analog and mixed-signal platform solutions for communications, Internet of Things (IoT), consumer, computing, industrial, and automotive applications. Its products include MOSFETs, IGBTs, AC-DC/DC-DC converters, light-emitting diode (LED) drivers, regulators, power management integrated circuits (PMICs), and industrial applications such as power suppliers, e-bikes, photovoltaic inverters, LED lighting, and motor drives. The company was founded on November 26, 2003 and is headquartered in Cheongju-si, South Korea.

MagnaChip Semiconductor Corp

MagnaChip Semiconductor is currently a focal point for investors due to intensifying speculation regarding a potential buyout or strategic sale, with the community closely tracking rumors involving key South Korean players like LX Semicon. Sentiment is further bolstered by the company's aggressive stock repurchase program, significant cash position, and a pivot toward high-growth sectors like automotive power solutions and OLED technology.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying on massive volume as investors bet on the companys role in critical AI infrastructure and its potential as a key player in the optical interconnect market. The community is actively discussing the stock's significant momentum, speculation regarding potential hyperscaler partnerships, and the intense pressure on short sellers amid a tightening pool of available shares.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinear is currently trending as investors debate whether the stock represents a significant long-term growth opportunity tied to AI infrastructure or an overextended, overbought asset. The community is sharply divided between bulls citing massive revenue growth and demand for data center optics, and skeptics who are warning of a potential rug-pull due to high RSI levels and lack of historical profitability.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy's Nasdaq debut is driving intense market interest as investors flock to the Amazon-backed nuclear firm, which is positioned as a key player in solving the power demands of AI data centers. The community is actively debating the company's valuation and project pipeline compared to peers while closely watching for price momentum following its significantly oversubscribed IPO.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Compass Therapeutics is trending as investors monitor the upcoming release of Phase 2/3 clinical trial results for tovecimig in biliary tract cancer, with the community closely tracking the potential survival benefits versus historical standards. Traders are focused on the volatility surrounding this binary event, debating whether the recent price movement and pre-announcement indicate positive data or institutional positioning.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
